11 februari 2005: Bron: J Pediatr Hematol Oncol. 2004 Oct;26(10):631-5.

Avemar, een gefermenteerd tarwekiem extract vermindert en voorkomt neutropenie en koorts bij kinderen die chemokuren volgen wegens kanker met solide tumoren blijkt uit gerandomiseerde studie bij 44 kinderen. 24.8% van de kinderen in de MSC group kreeg last van neutropenie tegenover 43.4% in de controle groep (Wilcoxon signed rank test, P < 0.05). Een significant resultaat dus. Op de ontwikkeling van de ziekte zelf werd geen verschil gevonden, geen enkel kind uit beide groepen toonde progressie tijdens de behandeling. De kwaliteit van leven werd dus door Avemar beduidend beter in de groep kinderen die dit kreeg toegediend

Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients.

Garami M, Schuler D, Babosa M, Borgulya G, Hauser P, Muller J, Paksy A, Szabo E, Hidvegi M, Fekete G.
Second Department of Pediatrics, School of Medicine, Semmelweis University, Budapest, Hungary. miklos.garami@gyer2.sote.hu

PURPOSE: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC.

METHODS: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM = T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups.

RESULTS: During the treatment (follow-up) period, there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P < 0.05).

CONCLUSIONS: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers.

PMID: 15454833 [PubMed - indexed for MEDLINE]

Plaats een reactie ...

Reageer op "Avemar, een gefermenteerd tarwekiem extract vermindert en voorkomt neutropenie en koorts bij kinderen die chemokuren volgen wegens kanker met solide tumoren."


Gerelateerde artikelen
 

Gerelateerde artikelen

Avemar, een gefermenteerd >> Avemar, een gefermenteerd >>